Status quo of hypercoagulation as a prognostic indicator following neoadjuvant immunochemotherapy in locally advanced gastric cancer

Gastric cancer remains a major cause of cancer-related mortality worldwide, with immunotherapy emerging as a promising treatment strategy. Neoadjuvant immune checkpoint therapy has shown potential in enhancing antitumor responses and improving surgical outcomes. However, its effects on systemic coagulation and thrombotic risk remain poorly understood. This study aims to investigate the relationship between neoadjuvant immune checkpoint therapy and coagulation dynamics in patients with gastric cancer, exploring potential mechanisms that may contribute to a hypercoagulable state. By assessing coagulation markers, thrombotic events, and inflammatory responses, this research seeks to provide insights into the interplay between immune modulation and hemostatic alterations. A better understanding of these interactions may help optimize patient management and guide thromboprophylaxis strategies in this clinical setting.